GSK: UBS reiterates its recommendation on the share

(CercleFinance.com) - The analyst confirms his buy recommendation on the share, with an unchanged target price of 2040 pence, representing 20% upside potential.


"GSK 1Q exceed expectations, driving a small FY upgrade. We see undemanding valuation given visibility of growth and watch for progress on Zantac & key catalysts" UBS says.

It adds that it expects sales growth of 4% and EPS growth of 6% in FY 2024, while its forecasts are 2% below the recent consensus provided by the company.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.